Rivaroxaban, one of the direct Factor Xa (FXa) inhibitors, is an oral anticoagulant approved for stroke prevention in patients with direct oral anticoagulants (DOACs) eligible for atrial fibrillation (AF) [1]. Here, F10 is linked to atrial fibrillation.